Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2018

Open Access 01-12-2018 | Research

Specificity of the IgG antibody response to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale MSP119 subunit proteins in multiplexed serologic assays

Authors: Jeffrey W. Priest, Mateusz M. Plucinski, Curtis S. Huber, Eric Rogier, Bunsoth Mao, Christopher J. Gregory, Baltazar Candrinho, James Colborn, John W. Barnwell

Published in: Malaria Journal | Issue 1/2018

Login to get access

Abstract

Background

Multiplex bead assays (MBA) that measure IgG antibodies to the carboxy-terminal 19-kDa sub-unit of the merozoite surface protein 1 (MSP119) are currently used to determine malaria seroprevalence in human populations living in areas with both stable and unstable transmission. However, the species specificities of the IgG antibody responses to the malaria MSP119 antigens have not been extensively characterized using MBA.

Methods

Recombinant Plasmodium falciparum (3D7), Plasmodium malariae (China I), Plasmodium ovale (Nigeria I), and Plasmodium vivax (Belem) MSP119 proteins were covalently coupled to beads for MBA. Threshold cut-off values for the assays were estimated using sera from US citizens with no history of foreign travel and by receiver operator characteristic curve analysis using diagnostic samples. Banked sera from experimentally infected chimpanzees, sera from humans from low transmission regions of Haiti and Cambodia (N = 12), and elutions from blood spots from humans selected from a high transmission region of Mozambique (N = 20) were used to develop an antigen competition MBA for antibody cross-reactivity studies. A sub-set of samples was further characterized using antibody capture/elution MBA, IgG subclass determination, and antibody avidity measurement.

Results

Total IgG antibody responses in experimentally infected chimpanzees were species specific and could be completely suppressed by homologous competitor protein at a concentration of 10 μg/ml. Eleven of 12 samples from the low transmission regions and 12 of 20 samples from the high transmission area had antibody responses that were completely species specific. For 7 additional samples, the P. falciparum MSP119 responses were species specific, but various levels of incomplete heterologous competition were observed for the non-P. falciparum assays. A pan-malaria MSP119 cross-reactive antibody response was observed in elutions of blood spots from two 20–30 years old Mozambique donors. The antibody response from one of these two donors had low avidity and skewed almost entirely to the IgG3 subclass.

Conclusions

Even when P. falciparum, P. malariae, P. ovale, and P. vivax are co-endemic in a high transmission setting, most antibody responses to MSP119 antigens are species-specific and are likely indicative of previous infection history. True pan-malaria cross-reactive responses were found to occur rarely.
Appendix
Available only for authorised users
Literature
1.
Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814.PubMedPubMedCentralCrossRef
2.
Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.PubMedPubMedCentralCrossRef
3.
Rutledge GG, Bohme U, Sanders M, Reid AJ, Cotton JA, Maiga-Ascofare O, et al. Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature. 2017;542:101–4.PubMedPubMedCentralCrossRef
4.
Rutledge GG, Marr I, Huang GKL, Auburn S, Marfurt J, Sanders M, et al. Genomic Characterization of recrudescent Plasmodium malariae after treatment with artemether/lumefantrine. Emerg Infect Dis. 2017;23:1300–7.PubMedPubMedCentralCrossRef
5.
Betson M, Clifford S, Stanton M, Kabatereine NB, Stothard JR. Emergence of non falciparum Plasmodium infection despite regular artemisinin combination therapy in an 18-month longitudinal study of Ugandan children and their mothers. J Infect Dis. 2018;217:1099–109.PubMedPubMedCentralCrossRef
6.
Roucher C, Rogier C, Sokhna C, Tall A, Trape JF. A 20-year longitudinal study of Plasmodium ovale and Plasmodium malariae prevalence and morbidity in a West African population. PLoS ONE. 2014;9:e87169.PubMedPubMedCentralCrossRef
7.
Langford S, Douglas NM, Lampah DA, Simpson JA, Kenangalem E, Sugiarto P, et al. Plasmodium malariae infection associated with a high burden of anemia: a hospital-based surveillance study. PLoS Negl Trop Dis. 2015;9:e0004195.PubMedPubMedCentralCrossRef
8.
Doderer-Lang C, Atchade PS, Meckert L, Haar E, Perrotey S, Filisetti D, et al. The ears of the African elephant: unexpected high seroprevalence of Plasmodium ovale and Plasmodium malariae in healthy populations in Western Africa. Malar J. 2014;13:240.PubMedPubMedCentralCrossRef
9.
10.
Livingstone FB. The Duffy blood groups, vivax malaria, and malaria selection in human populations: a review. Hum Biol. 1984;56:413–25.PubMed
11.
Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, et al. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774.PubMedPubMedCentralCrossRef
12.
Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med. 1976;295:302–4.PubMedCrossRef
13.
Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Ratsimbasoa A, et al. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci USA. 2010;107:5967–71.PubMedCrossRefPubMedCentral
14.
Howes RE, Reiner RC Jr, Battle KE, Longbottom J, Mappin B, Ordanovich D, et al. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis. 2015;9:e0004222.PubMedPubMedCentralCrossRef
15.
Poirier P, Doderer-Lang C, Atchade PS, Lemoine JP, de l’Isle MC, Abou-Bacar A, et al. The hide and seek of Plasmodium vivax in West Africa: report from a large-scale study in Beninese asymptomatic subjects. Malar J. 2016;15:570.PubMedPubMedCentralCrossRef
16.
Ngassa Mbenda HG, Das A. Molecular evidence of Plasmodium vivax mono and mixed malaria parasite infections in Duffy-negative native Cameroonians. PLoS ONE. 2014;9:e103262.PubMedPubMedCentralCrossRef
17.
Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis. BMC Med. 2014;12:150.PubMedPubMedCentralCrossRef
18.
Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med. 2010;7:e1000218.PubMedPubMedCentralCrossRef
19.
Folegatti PM, Siqueira AM, Monteiro WM, Lacerda MV, Drakeley CJ, Braga EM. A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection. Malar J. 2017;16:107.PubMedPubMedCentralCrossRef
20.
Corran P, Coleman P, Riley E, Drakeley C. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol. 2007;23:575–82.PubMedCrossRef
21.
Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, Carneiro I, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA. 2005;102:5108–13.PubMedCrossRefPubMedCentral
22.
Cunha MG, Silva ES, Sepulveda N, Costa SP, Saboia TC, Guerreiro JF, et al. Serologically defined variations in malaria endemicity in Para state, Brazil. PLoS ONE. 2014;9:e113357.PubMedPubMedCentralCrossRef
23.
Wong J, Hamel MJ, Drakeley CJ, Kariuki S, Shi YP, Lal AA, et al. Serological markers for monitoring historical changes in malaria transmission intensity in a highly endemic region of Western Kenya, 1994–2009. Malar J. 2014;13:451.PubMedPubMedCentralCrossRef
24.
Cook J, Reid H, Iavro J, Kuwahata M, Taleo G, Clements A, et al. Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J. 2010;9:169.PubMedPubMedCentralCrossRef
25.
Rosas-Aguirre A, Llanos-Cuentas A, Speybroeck N, Cook J, Contreras-Mancilla J, Soto V, et al. Assessing malaria transmission in a low endemicity area of north-western Peru. Malar J. 2013;12:339.PubMedPubMedCentralCrossRef
26.
Rosas-Aguirre A, Speybroeck N, Llanos-Cuentas A, Rosanas-Urgell A, Carrasco-Escobar G, Rodriguez H, et al. Hotspots of malaria transmission in the Peruvian Amazon: rapid assessment through a parasitological and serological survey. PLoS ONE. 2015;10:e0137458.PubMedPubMedCentralCrossRef
27.
Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, et al. Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS ONE. 2009;4:e6083.PubMedPubMedCentralCrossRef
28.
Arnold BF, Priest JW, Hamlin KL, Moss DM, Colford JM Jr, Lammie PJ. Serological measures of malaria transmission in Haiti: comparison of longitudinal and cross-sectional methods. PLoS ONE. 2014;9:e93684.PubMedPubMedCentralCrossRef
29.
Metcalf CJ, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet. 2016;388:728–30.PubMedPubMedCentralCrossRef
30.
Jepsen MP, Roser D, Christiansen M, Olesen Larsen S, Cavanagh DR, et al. Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. J Immunol Methods. 2012;384:62–70.PubMedCrossRef
31.
Kerkhof K, Canier L, Kim S, Heng S, Sochantha T, Sovannaroth S, et al. Implementation and application of a multiplex assay to detect malaria-specific antibodies: a promising tool for assessing malaria transmission in Southeast Asian pre-elimination areas. Malar J. 2015;14:338.PubMedPubMedCentralCrossRef
32.
Koffi D, Toure AO, Varela ML, Vigan-Womas I, Beourou S, Brou S, Ehouman MF, et al. Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX). Malar J. 2015;14:509.PubMedPubMedCentralCrossRef
33.
Priest JW, Jenks MH, Moss DM, Mao B, Buth S, Wannemuehler K, et al. Integration of multiplex bead assays for parasitic diseases into a national, population-based serosurvey of women 15–39 years of age in Cambodia. PLoS Negl Trop Dis. 2016;10:e0004699.PubMedPubMedCentralCrossRef
34.
Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun. 1997;65:1606–14.PubMedPubMedCentral
35.
Egan AF, Chappel JA, Burghaus PA, Morris JS, McBride JS, Holder AA, et al. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun. 1995;63:456–66.PubMedPubMedCentral
36.
Muerhoff AS, Birkenmeyer LG, Coffey R, Dille BJ, Barnwell JW, Collins WE, et al. Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates. Clin Vaccine Immunol. 2010;17:1631–8.PubMedPubMedCentralCrossRef
37.
Holder AA. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology. 2009;136:1445–56.PubMedCrossRef
38.
Birkenmeyer L, Muerhoff AS, Dawson GJ, Desai SM. Isolation and characterization of the MSP1 genes from Plasmodium malariae and Plasmodium ovale. Am J Trop Med Hyg. 2010;82:996–1003.PubMedPubMedCentralCrossRef
39.
Babon JJ, Morgan WD, Kelly G, Eccleston JF, Feeney J, Holder AA. Structural studies on Plasmodium vivax merozoite surface protein-1. Mol Biochem Parasitol. 2007;153:31–40.PubMedCrossRef
40.
Bousema T, Youssef RM, Cook J, Cox J, Alegana VA, Amran J, et al. Serologic markers for detecting malaria in areas of low endemicity, Somalia, 2008. Emerg Infect Dis. 2010;16:392–9.PubMedPubMedCentralCrossRef
41.
Plucinski MM, Candrinho B, Chambe G, Muchanga J, Muguande O, Matsinhe G, et al. Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. PLoS Negl Trop Dis. 2018;12:e0006278.PubMedPubMedCentralCrossRef
42.
Amanfo SA, Mduluza T, Midzi N, Cavanagh DR, Mutapi F. Seroepidemiology of Plasmodium species infections in Zimbabwean population. Malar J. 2016;15:267.PubMedPubMedCentralCrossRef
43.
Priest JW, Moss DM, Won K, Todd CW, Henderson L, Jones CC, Wilson M. Multiplex assay detection of immunoglobulin G antibodies that recognize Babesia microti antigens. Clin Vaccine Immunol. 2012;19:1539–48.PubMedPubMedCentralCrossRef
44.
Scobie HM, Mao B, Buth S, Wannemuehler KA, Sorensen C, Kannarath C, et al. Tetanus immunity among women aged 15 to 39 years in Cambodia: a national population-based serosurvey, 2012. Clin Vaccine Immunol. 2016;23:546–54.PubMedPubMedCentralCrossRef
45.
Mao B, Chheng K, Wannemuehler K, Vynnycky E, Buth S, Soeung SC, et al. Immunity to polio, measles and rubella in women of child-bearing age and estimated congenital rubella syndrome incidence, Cambodia, 2012. Epidemiol Infect. 2015;143:1858–67.PubMedCrossRef
46.
Collins WE, McClure HM, Strobert E, Filipski V, Skinner JC, Stanfill PS, et al. Infection of chimpanzees with the Uganda I/CDC strain of Plasmodium malariae. Am J Trop Med Hyg. 1990;42:99–103.PubMedCrossRef
47.
Collins WE, Schwartz IK, Skinner JC, Broderson JR. Studies on the Uganda I/CDC strain of Plasmodium malariae in Bolivian Aotus monkeys and various anophelines. J Parasitol. 1984;70:677–81.PubMedCrossRef
48.
Collins WE, Pappaioanou M, McClure HM, Swenson RB, Strobert E, Skinner JC, et al. Infection of chimpanzees with Nigerian I/CDC strain of Plasmodium ovale. Am J Trop Med Hyg. 1987;37:455–9.PubMedCrossRef
49.
Sullivan JS, Morris CL, McClure HM, Strobert E, Richardson BB, Galland GG, et al. Plasmodium vivax infections in chimpanzees for sporozoite challenge studies in monkeys. Am J Trop Med Hyg. 1996;55:344–9.PubMedCrossRef
50.
Rogier E, Wiegand R, Moss D, Priest J, Angov E, Dutta S, et al. Multiple comparisons analysis of serological data from an area of low Plasmodium falciparum transmission. Malar J. 2015;14:436.PubMedPubMedCentralCrossRef
51.
Moss DM, Montgomery JM, Newland SV, Priest JW, Lammie PJ. Detection of Cryptosporidium antibodies in sera and oral fluids using multiplex bead assay. J Parasitol. 2004;90:397–404.PubMedCrossRef
52.
Dame JB, Williams JL, McCutchan TF, Weber JL, Wirtz RA, Hockmeyer WT, et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984;225:593–9.PubMedCrossRef
53.
Ballou WR, Rothbard J, Wirtz RA, Gordon DM, Williams JS, Gore RW, et al. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparum. Science. 1985;228:996–9.PubMedCrossRef
54.
Benitez A, Priest JW, Ehigiator HN, McNair N, Mead JR. Evaluation of DNA encoding acidic ribosomal protein P2 of Cryptosporidium parvum as a potential vaccine candidate for cryptosporidiosis. Vaccine. 2011;29:9239–45.PubMedPubMedCentralCrossRef
55.
Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, Beach MJ, Lammie PJ. Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis. Am J Trop Med Hyg. 2011;85:229–37.PubMedPubMedCentralCrossRef
56.
Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, et al. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J. 2008;7:195.PubMedPubMedCentralCrossRef
57.
Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006;309:200–4.PubMedCrossRef
58.
Hamlin KL, Moss DM, Priest JW, Roberts J, Kubofcik J, Gass K, et al. Longitudinal monitoring of the development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a highly endemic area of Haiti. PLoS Negl Trop Dis. 2012;6:e1941.PubMedPubMedCentralCrossRef
59.
Tsang VC, Wilkins PP. Optimum dissociating condition for immunoaffinity and preferential isolation of antibodies with high specific activity. J Immunol Methods. 1991;138:291–9.PubMedCrossRef
60.
Prince HE, Wilson M. Simplified assay for measuring Toxoplasma gondii immunoglobulin G avidity. Clin Diagn Lab Immunol. 2001;8:904–8.PubMedPubMedCentral
61.
Papadopoulos JS, Agarwala R. COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007;23:1073–9.PubMedCrossRef
62.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.PubMed
63.
64.
Guimaraes LO, Wunderlich G, Alves JM, Bueno MG, Rohe F, Catao-Dias JL, et al. Merozoite surface protein-1 genetic diversity in Plasmodium malariae and Plasmodium brasilianum from Brazil. BMC Infect Dis. 2015;15:529.PubMedPubMedCentralCrossRef
65.
Putaporntip C, Hughes AL, Jongwutiwes S. Low level of sequence diversity at merozoite surface protein-1 locus of Plasmodium ovale curtisi and P. ovale wallikeri from Thai isolates. PLoS One. 2013;8:e58962.PubMedPubMedCentralCrossRef
66.
Putaporntip C, Jongwutiwes S, Sakihama N, Ferreira MU, Kho WG, Kaneko A, et al. Mosaic organization and heterogeneity in frequency of allelic recombination of the Plasmodium vivax merozoite surface protein-1 locus. Proc Natl Acad Sci USA. 2002;99:16348–53.PubMedCrossRefPubMedCentral
67.
Jongwutiwes S, Tanabe K, Kanbara H. Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol. 1993;59:95–100.PubMedCrossRef
68.
del Portillo HA, Longacre S, Khouri E, David PH. Primary structure of the merozoite surface antigen 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium species. Proc Natl Acad Sci USA. 1991;88:4030–4.PubMedCrossRefPubMedCentral
69.
Rayner JC, Liu W, Peeters M, Sharp PM, Hahn BH. A plethora of Plasmodium species in wild apes: a source of human infection? Trends Parasitol. 2011;27:222–9.PubMedPubMedCentralCrossRef
70.
Howes RE, Patil AP, Piel FB, Nyangiri OA, Kabaria CW, Gething PW, et al. The global distribution of the Duffy blood group. Nat Commun. 2011;2:266.PubMedCrossRef
71.
Stanisic DI, Fowkes FJ, Koinari M, Javati S, Lin E, Kiniboro B, et al. Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun. 2015;83:646–60.PubMedPubMedCentralCrossRef
72.
Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun. 2009;77:1165–74.PubMedPubMedCentralCrossRef
73.
Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM, et al. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun. 2006;74:257–64.PubMedPubMedCentralCrossRef
74.
Mehrizi AA, Asgharpour S, Salmanian AH, Djadid ND, Zakeri S. IgG subclass antibodies to three variants of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(19)) in an area with unstable malaria transmission in Iran. Acta Trop. 2011;119:84–90.PubMedCrossRef
75.
Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, Oloo AJ, et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun. 1996;64:2716–23.PubMedPubMedCentral
76.
Scopel KK, Fontes CJ, Ferreira MU, Braga EM. Factors associated with immunoglobulin G subclass polarization in naturally acquired antibodies to Plasmodium falciparum merozoite surface proteins: a cross-sectional survey in Brazilian Amazonia. Clin Vaccine Immunol. 2006;13:810–3.PubMedPubMedCentralCrossRef
77.
Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun. 2008;76:759–66.PubMedCrossRef
78.
Cavanagh DR, Dobano C, Elhassan IM, Marsh K, Elhassan A, Hviid L, et al. Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun. 2001;69:1207–11.PubMedPubMedCentralCrossRef
79.
Cortes A, Mellombo M, Masciantonio R, Murphy VJ, Reeder JC, Anders RF. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect Immun. 2005;73:422–30.PubMedPubMedCentralCrossRef
80.
Kusi KA, Dodoo D, Bosomprah S, van der Eijk M, Faber BW, Kocken CH, Remarque EJ. Measurement of the plasma levels of antibodies against the polymorphic vaccine candidate apical membrane antigen 1 in a malaria-exposed population. BMC Infect Dis. 2012;12:32.PubMedPubMedCentralCrossRef
81.
Oki M, Asai S, Saito-Nakano Y, Nakayama T, Tanaka Y, Tachibana H, et al. A case of quadruple malaria infection imported from Mozambique to Japan. Am J Trop Med Hyg. 2014;90:1098–101.PubMedPubMedCentralCrossRef
82.
Kusi KA, Manu EA, Manful Gwira T, Kyei-Baafour E, Dickson EK, Amponsah JA, et al. Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. PLoS ONE. 2017;12:e0185303.PubMedPubMedCentralCrossRef
Metadata
Title
Specificity of the IgG antibody response to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale MSP119 subunit proteins in multiplexed serologic assays
Authors
Jeffrey W. Priest
Mateusz M. Plucinski
Curtis S. Huber
Eric Rogier
Bunsoth Mao
Christopher J. Gregory
Baltazar Candrinho
James Colborn
John W. Barnwell
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2018
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-018-2566-0

Other articles of this Issue 1/2018

Malaria Journal 1/2018 Go to the issue

Research

Inter-sectoral approaches for the prevention and control of malaria among the mobile and migrant populations: a scoping review

Research

A multiplex assay for the sensitive detection and quantification of male and female Plasmodium falciparum gametocytes

Research

Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium

Research

The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates

Research

Association between timing and number of antenatal care visits on uptake of intermittent preventive treatment for malaria during pregnancy among Malawian women

Research

Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits